14.2 Clinical Study in Patients with Type 2 Diabetes Uncontrolled on OAD Treatment A total of 1170 patients with type 2 diabetes were randomized in an open-label, 30-week, active-controlled study (Study A: NCT05058147) to evaluate the efficacy and safety of SOLIQUA 100/33 compared to the individual components, insulin glargine 100 units/mL and lixisenatide
If you feel anything strange or notice something odd with your eyes, get help from a doctor right away
Tirzepatide, the more potent of the two, actually carries a lower incidence of GI side effects
Step 3: Disclose all medications
Las limitaciones incluyen que, aunque todos los usuarios de agonistas de GLP-1 tenan antecedentes de obesidad sin diabetes, no se sabe si todos los agonistas de GLP-1 se usaron para perder peso
Research findings indicate that after 3 months of KD use, the frequency of epileptic seizures decreases by at least 50% (74)